-transparent.png){kind=logo}
In a double-blind phenelzine controlled clinical trial, 49 depressed outpatients were treated with a fixed dose of amitriptyline (AMI) 150 mg/day for 6 weeks. No significant relationships were found between steady-state plasma levels of AMI and its metabolite, nortriptyline, at 4 weeks and therapeutic response at 6 weeks or side effects. In the patient subgroup with more severe endogenous symptoms, there was a general trend for a weak positive association between AMI plasma levels and clinical improvement. Plasma tricyclic determinations appear to have little if any predictive value for antidepressant effect in outpatients treated with AMI.
Related Publications
D S Robinson, and
T B Cooper, and
C L Ravaris, and
J O Ives, and
A Nies, and
D Bartlett, and
K R Lamborn
January 1983,
Psychopharmacology,
D S Robinson, and
T B Cooper, and
C L Ravaris, and
J O Ives, and
A Nies, and
D Bartlett, and
K R Lamborn
May 1978,
The American journal of psychiatry,
D S Robinson, and
T B Cooper, and
C L Ravaris, and
J O Ives, and
A Nies, and
D Bartlett, and
K R Lamborn
November 1982,
The Journal of clinical psychiatry,
D S Robinson, and
T B Cooper, and
C L Ravaris, and
J O Ives, and
A Nies, and
D Bartlett, and
K R Lamborn
August 1977,
The British journal of psychiatry : the journal of mental science,
D S Robinson, and
T B Cooper, and
C L Ravaris, and
J O Ives, and
A Nies, and
D Bartlett, and
K R Lamborn
April 1982,
The Journal of pharmacy and pharmacology,
D S Robinson, and
T B Cooper, and
C L Ravaris, and
J O Ives, and
A Nies, and
D Bartlett, and
K R Lamborn
December 1977,
Pharmakopsychiatrie, Neuro-Psychopharmakologie,
D S Robinson, and
T B Cooper, and
C L Ravaris, and
J O Ives, and
A Nies, and
D Bartlett, and
K R Lamborn
October 1977,
Diseases of the nervous system,
D S Robinson, and
T B Cooper, and
C L Ravaris, and
J O Ives, and
A Nies, and
D Bartlett, and
K R Lamborn
March 2003,
European psychiatry : the journal of the Association of European Psychiatrists,
D S Robinson, and
T B Cooper, and
C L Ravaris, and
J O Ives, and
A Nies, and
D Bartlett, and
K R Lamborn
August 1975,
British journal of clinical pharmacology,
D S Robinson, and
T B Cooper, and
C L Ravaris, and
J O Ives, and
A Nies, and
D Bartlett, and
K R Lamborn
July 2002,
International clinical psychopharmacology,
